A Happy Tear Shed For Virus Efficacy
Sam Fazeli, Senior Healthcare Analyst, Bloomberg Intelligence
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Pfizer may be the first drugmaker to file for US regulatory authorization for its Covid-19 vaccine, which it says is 95% effective with no serious side effects. This comes right on the heels of news out of Moderna, which says its vaccine also stands at over 94%. With hopes rising that we may see a vaccine in distribution by the end of the year, we speak to Sam Fazeli, Senior Healthcare Analyst at Bloomberg Intelligence, about whether this is truly a cause for excitement.
Image Credit: Shutterstock
Produced by: Dayana Mustak
Presented by: Lyn Mak, Roshan Kanesan, Wong Shou Ning
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: Politics, Law and Legal Matters, Health Policy, Diseases and Conditions, Mental Health, Healthy Living, Fitness, Science, Business Analysis, Trends and Forecasts, Markets, Social Issues, Medical Innovation and Technology, Investments